In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Time-dependent impact of pre-infarction angina pectoris and intermittent claudication on mortality from myocardial infarction as measures of endogenous local and remote ischemic preconditioning

Session Poster session 3

Speaker Hans Erik Botker

Event : ESC Congress 2014

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease and Comorbidities
  • Session type : Poster Session

Authors : M Schmidt (Aarhus,DK), EP Horvath-Puho (Aarhus,DK), LP Pedersen (Aarhus,DK), HT Sorensen (Aarhus,DK), HE Botker (Aarhus,DK)

Authors:
M. Schmidt1 , E.P. Horvath-Puho1 , L.P. Pedersen1 , H.T. Sorensen1 , H.E. Botker2 , 1Aarhus University Hospital, Department of Clinical Epidemiology - Aarhus - Denmark , 2Aarhus University Hospital, Department of Cardiology - Aarhus - Denmark ,

Citation:
European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 494

Purpose: Local and remote ischemic preconditioning are cardioprotective mechanisms. We examined the time-dependent impact of pre-infarction angina pectoris and intermittent claudication on short- and long-term mortality following myocardial infarction.

Methods: We conducted a nationwide population-based cohort study using medical registries. We identified all first-time hospitalizations for myocardial infarction in our country between 1996 and 2012. We used Cox regression to compute mortality rate ratios (MRRs) within 30 days, 31-365 days, 1-5 years, and 6-10 years comparing patients with and without previous angina or intermittent claudication. We repeated the analyses according to time between first diagnosis of angina or intermittent claudication and subsequent myocardial infarction (≤7 days, 8-14 days, 15-30 days, 31-90 days, and >90 days). We adjusted for age, sex, calendar period of diagnosis, and comorbidities.

Results: We identified 150,480 patients with first-time myocardial infarction, among whom 23,705 (15.8%) had previously been diagnosed with stable angina, 3,806 (2.5%) with unstable angina, and 3,740 (2.5%) with intermittent claudication. Compared to patients without previous stable or unstable angina, the adjusted 30-day MRR was 0.85 (95% CI: 0.82-0.88) for patients with prior stable angina and 0.67 (95% CI: 0.61-0.74) for patients with prior unstable angina. The mortality reduction was higher the shorter time interval between angina presentation and myocardial infarction and higher for unstable than stable angina. Thus, the 30-day MRR was 0.33 (95% CI: 0.20-0.55) for patients presenting with unstable angina within 7 days before myocardial infarction compared to myocardial infarction patients without previous angina. Beyond 30-days of follow-up, there was no additional survival benefit of pre-infarction angina. Independent of time to myocardial infarction, patients with intermittent claudication had increased short and long-term mortality.

Conclusions: Pre-infarction angina, but not intermittent claudication, improved 30-day mortality following myocardial infarction. The dependency of time and angina type, suggests an effect of endogenous local ischemic preconditioning. The results for intermittent claudication may reflect an absent remote preconditioning effect or the higher comorbidity burden among these patients.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are